Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETERMINE: Alectinib in Rare ALK-Positive Cancers
NCT05770037Phase 3Recruiting
- Sponsor
- Cancer Research UK
- Start
- Dec 2023
- Primary completion
- Oct 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of alectinib in solid tumor, hematological malignancy, sponsored by Cancer Research UK. Started Dec 2023; status: recruiting.
02
Drugs
alectinib
03
Conditions
solid tumorhematological malignancy
Beyond the preview
Go deeper on NCT05770037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770037.